Weekly schedule of docetaxel in breast cancer: Evaluation of response and toxicity

Breast Cancer

Volumn 10, Issue 1, 2003, Pages 10-14

  Kuroi, Katsumasa ^a,b   Bando, Hiroko ^a   Saji, Shigehira ^a   Toi, Masakazu ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^b SHOWA UNIVERSITY KOTO TOYOSU HOSPITAL   (Japan)

Author keywords

Breast cancer; Docetaxel; Response; Toxicity; Weekly schedule

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; DRUG DERIVATIVE; PACLITAXEL; TAXOID;

BREAST TUMOR; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; HUMAN; MAXIMUM TOLERATED DOSE; REVIEW;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; PACLITAXEL; TAXOIDS;

EID: 0041308330     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02967619     Document Type: Review

References (28)

1. Bonneterre J, Spielman M, Guastalla JP, et al: Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience. Eur J Cancer 35:1431-1439, 1999. (Pubitemid 29454643)
2. Adachi I, Watanabe T, Takashima S, et al: A late phase 11 study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. BrJ Cancer 73:210-216, 1996. (Pubitemid 26028336)
3. Fumoleau P, Chevallier B, Kerbrat P, et al: A multicentre phase 1I study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. Ann Oncol 7:165-171, 1996. (Pubitemid 26094881)
4. O'Brien ME, Leonard RC, Barrett-Lee PJ, et al: Docetaxel in the community setting: an analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the Ut-UK Study Group. Ann Oncol 10:205-210, 1999. (Pubitemid 29113181)
5. Salminen E, Bergman M, Huhtala S, et al: Docetaxel: standard recommended dose of 100 mg/m 2 is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-A phase II single-center study. J Clin Oncol 17:1127, 1999.
6. Seidman AD, Hudis CA, Albanel J, et al: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16:3353-3361, 1998. (Pubitemid 28481632)
7. Burstein HJ, Manola J, Younger J, et al: Docetaxel administered on a weekly basis for metastatic breast cancer.J Clin Onco118:1212-1219, 2000. (Pubitemid 30159838)
8. Greco FA: Docetaxel (Taxotere) administered in weekly schedules. Semin Onco126:28-31, 1999. (Pubitemid 29383335)
9. Bunnell C: Current perspectives for treatment of breast cancer. Breast Cancer 7:380-388, 2000.
10. Baselga J, Tabernero JM: Weekly docetaxel in breast cancer: applying clinical data to patient therapy. Oncologist 6 (Suppl 3):26-29, 2001. (Pubitemid 32423183)
11. Löffler TM: Is there a place for "dose-dense" weekly schedules of the taxoids? Semin Onco125:32-34, 1998. (Pubitemid 28562737)
12. Hainsworth JD, Burris HA III, Erland JB, et al: Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 16:2164-2168, 1998. (Pubitemid 28265054)
13. Hainsworth JD, Burris HA IU, Greco FA: Weekly administration of docetaxel (Taxotere): summary of clinical data. Semin Onco126:19-24, 1999. (Pubitemid 29368113)
14. Briasoulis E, Karavasilis V, Anastasopoulos D, et al: Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration. Ann Oncol 10:701-706, 1999. (Pubitemid 29342376)
15. Kouroussis C, Agelaki S, Mavroudis D, et al: A dose escalation study of weekly docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 46:488-492, 2000.
16. Kuroi K, Bando H, Nagai S, et al: Efficacy of weekly docetaxel therapy for advanced or recurrent breast cancer. Jpn J Cancer Chemother 28:797-802, 2001.
17. Hainsworth JD, Burris HA Ill, Yardley DA, et ah Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase 11 trial. J Clin Oncol 19:3500-3505, 2001. (Pubitemid 32730087)
18. Stemmler HJ, Gutschow K, Sommer H, et al: Weekly docetaxel (Taxotere) in patients with metastatic breast cancer. Ann Oncol 12:1393-1398, 2001. (Pubitemid 33100243)
19. Aihara T, Kim Y, Takatsuka Y: Phase II study of weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 13:286-292, 2002. (Pubitemid 34704982)
20. Kim Y, Takatsuka Y, Gotoh K, et al: Pharmacological study of weekly docetaxel in patients with metastatic breast cancer. Jpn J Cancer Chemother 26:1437-1441, 1999.
21. Piccart MJ, Klijn J, Paridaens R, et al: Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.J Clin Oncol 15:3149-3155, 1997. (Pubitemid 27377507)
22. Brink HM, Beex LV: Punctal and canalicular stenosis associated with systemic fluorouracil therapy. Report of five cases and review of the literature. Doc Ophthaltool 90:1-6, 1995.
23. Curran CF, Luce JK: Ocular adverse reactions associated with adriamycin (doxorubicin). Am J Ophthalmol 108:709-711, 1989. (Pubitemid 20013095)
24. Valero V, Holmes FA, Walters RS, et al: Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886-2894, 1995.
25. Esmaeli B, Valero V, Ahmadi MA, et al: Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect. Ophthalmology 108:994-995, 2001. (Pubitemid 32374259)
26. Esmaeli B, Hortobagyi G, Esteva F, et al: Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect. Ann Oncol 13:218-221, 2002. (Pubitemid 34704972)
27. Esteva FJ, Valero V, Booser D, et al: Phase 1I study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Onco120:1800-1808, 2002. (Pubitemid 34273269)
28. Frasci G, Comella P, D'Aiuto G, et al: Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG). Ann Oncol 11:367-371, 2000. (Pubitemid 30214679)